E75.21 is a valid billable ICD-10 diagnosis code for Fabry (-Anderson) disease . It is found in the 2021 version of the ICD-10 Clinical Modification (CM) and can be used in all HIPAA-covered transactions from Oct 01, 2020 - Sep 30, 2021 .
Genetic carrier of other disease. The 2019 edition of ICD-10-CM Z14.8 became effective on October 1, 2018. This is the American ICD-10-CM version of Z14.8 - other international versions of ICD-10 Z14.8 may differ.
E75.21 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2020 edition of ICD-10-CM E75.21 became effective on October 1, 2019. This is the American ICD-10-CM version of E75.21 - other international versions of ICD-10 E75.21 may differ.
2016 2017 2018 2019 Billable/Specific Code E75.21 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM E75.21 became effective on October 1, 2018. This is the American ICD-10-CM version of E75.21 - other international versions of ICD-10 E75.21 may differ.
Fabry disease is a rare inherited disorder of glycosphingolipid (fat) metabolism resulting from the absent or markedly deficient activity of the lysosomal enzyme, α-galactosidase A (α-Gal A). This disorder belongs to a group of diseases known as lysosomal storage disorders.
ICD-10 code R68. 8 for Other general symptoms and signs is a medical classification as listed by WHO under the range - Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified .
R68. 89 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM R68. 89 became effective on October 1, 2021.
ICD-10 code Z00. 01 for Encounter for general adult medical examination with abnormal findings is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .